Application of MALDI Imaging Mass Spectrometry in Drug Discovery and Development
Recorded On: 10/15/2020
Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) has emerged as a powerful technology in drug discovery and development for determining label-free distributions of drugs and their metabolites in tissues. In the past few years, MALDI IMS has been further advanced to achieve absolute quantification of drug distributions. Moreover, MALDI IMS has also been applied to map endogenous molecule distribution in the context of specific histological features or pathological phenotypes to provide a molecular basis for tissue histology/pathology, facilitating pathway analysis and understanding mechanistic principles of diseases. Here, representative examples will be presented to demonstrate how MALDI IMS is applied to quantitively visualize pharmacokinetics and identify localized molecular markers in drug discovery and development.
Fang Xie, PhD
Dr. Fang Xie is an Investigator and an Associate Fellow of GlaxoSmithKline plc. Dr. Xie is also a Diplomate of the American Board of Toxicology (D.A.B.T.). Dr. Xie received her Ph.D. from the State University of New York (SUNY) at Albany in 2011. She has extensive research background in the fields of drug metabolism, pharmacokinetics, and toxicology. Her key research interests include drug cellular disposition, drug-induced toxicities, and application of animal models. Dr. Xie serves as a regular reviewer for the journals Drug Metabolism and Disposition, Journal of Biochemical and Molecular Toxicology, and Xenobiotica. Her current investigations focus on application of imaging mass spectrometry to improve drug discovery and development. Dr. Xie is a founding member of Imaging Mass Spectrometry Society.